Which medications are being investigated for the treatment of pediatric neuroblastoma?

Updated: Oct 09, 2017
  • Author: Norman J Lacayo, MD; Chief Editor: Max J Coppes, MD, PhD, MBA  more...
  • Print
Answer

Other experimental therapies are currently under investigation for recurrent high-risk neuroblastoma, including aurora kinase inhibitors, antiangiogenic agents, histone deacetylase inhibitors, and therapeutic metaiodobenzylguanidine (MIBG). [22, 23]

A pilot trial that investigated a fixed dose of a unique anti-GD2 mAb, hu14.18K322A, combined with chemotherapy, cytokines, and haploidentical natural killer cells for 13 children with recurrent/refractory neuroblastoma reported a response rate of 61.5% (4 complete responses, 1 very good partial response, 3 partial responses and five had stable disease). One patient developed an unacceptable toxicity (grade 4 thrombocytopenia >35 days) and four patients discontinued treatment for adverse events. [24]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!